These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29741432)

  • 1. Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
    Adehin A; Adeagbo BA; Kennedy MA; Bolaji OO; Olugbade TA; Bolarinwa RA; Durosinmi MA
    Leuk Lymphoma; 2019 Jan; 60(1):216-221. PubMed ID: 29741432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
    Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
    Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
    Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
    J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
    Verboom MC; Visser L; Kouwen S; Swen JJ; Diepstraten J; Posthuma WF; Gelderblom H; van Lammeren D; Wilms EB
    Pharmacogenet Genomics; 2017 Jun; 27(6):223-226. PubMed ID: 28383355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population.
    Adehin A; Bolaji OO; Kennedy MA
    Drug Metab Pharmacokinet; 2017 Jun; 32(3):189-191. PubMed ID: 28427759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
    Yin SJ; Qi HM; Wang X; Zhang P; Lu Y; Wei MJ; Li P; Qi GZ; Lou YQ; Lu C; Zhang GL
    Pharmacogenet Genomics; 2017 Apr; 27(4):125-134. PubMed ID: 28099407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
    Barratt DT; Cox HK; Menelaou A; Yeung DT; White DL; Hughes TP; Somogyi AA
    Clin Pharmacokinet; 2017 Aug; 56(8):977-985. PubMed ID: 27995529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
    Dalle Fratte C; Gagno S; Roncato R; Polesel J; Zanchetta M; Buzzo M; Posocco B; De Mattia E; Borsatti R; Puglisi F; Foltran L; Guardascione M; Buonadonna A; Cecchin E; Toffoli G
    Br J Clin Pharmacol; 2023 Mar; 89(3):1089-1098. PubMed ID: 36178950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.
    Khan MS; Barratt DT; Somogyi AA
    Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
    Cargnin S; Ravegnini G; Soverini S; Angelini S; Terrazzino S
    Pharmacol Res; 2018 May; 131():244-254. PubMed ID: 29427770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.
    Tan ML; Yoshida K; Zhao P; Zhang L; Nolin TD; Piquette-Miller M; Galetin A; Huang SM
    Clin Pharmacol Ther; 2018 May; 103(5):854-867. PubMed ID: 28990182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.
    Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K
    Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.
    Vaidya S; Ghosh K; Shanmukhaiah C; Vundinti BR
    Eur J Pharmacol; 2015 Oct; 765():124-30. PubMed ID: 26300393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.